GlassScriptPhysician profile
Rumali Medagoda
NPI 1396882536
$9,890.90
in general payments reported to CMS, 2019-2025
29 companies · $2,565 in 2025
The $2,565 reported for 2025 was more than what 76% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $124 · 2021: $124 · 2022: $1,310 · 2023: $1,937 · 2024: $2,575 · 2025: $2,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,912 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,912.45 |
| Education | $164.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,094.00 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $1,174.16 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $951.23 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Csl Behring | $837.88 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pharming Healthcare, INC. | $554.62 | 2022-2025 | Ruconest |
| Pfizer INC. | $434.83 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $397.06 | 2019-2025 | |
| Grifols USA, LLC | $292.77 | 2021-2025 | Xembify, Prolastin-C Liquid |
| Abbvie INC. | $277.16 | 2022-2025 | |
| Kaleo, INC. | $274.40 | 2019-2024 | Auvi-Q |
| Genzyme Corporation | $257.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $253.96 | 2020-2025 | Cuvitru, Takhzyro |
| Amgen INC. | $245.00 | 2023-2025 | Tezspire |
| Genentech USA, INC. | $159.17 | 2019-2025 | Xolair |
| Shire North American Group INC | $149.77 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $94.17 | 2022-2023 | |
| Lilly USA, LLC | $92.60 | 2025 | Ebglyss |
| Optinose US, INC. | $77.80 | 2019-2025 | |
| Gc Biopharma USA, INC. | $45.87 | 2024-2025 | Alyglo, Alyglo |
| Ionis Pharmaceuticals, INC. | $45.53 | 2025 | Dawnzera |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.95 | 2024 | Spiriva Respimat |
| Ars Pharmaceuticals Operations, INC. | $25.70 | 2025 | Neffy |
| Galderma Laboratories, L.P. | $22.34 | 2025 | Nemluvio |
| Cycle Pharmaceuticals INC | $19.94 | 2025 | Sajazir |
| Biocryst US Sales Co., LLC | $19.21 | 2023 | Orladeyo |
| Blueprint Medicines Corporation | $18.46 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.03 | 2022 | |
| Alk-Abello, INC | $15.14 | 2019 | |
| Greer Laboratories, INC. | $13.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rumali Medagoda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.